The ability of antiviral formulation ViruSAL to inhibit SARS-CoV-2 infectivity
Researchers from Ireland used human bronchial epithelium models to evaluate the ability of a novel proprietary formulation called ViruSAL to inhibit SARS-CoV-2 infections.